Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Gross ProfitOther Operating ExpensesRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mainz Biomed N.V (MYNZ) EBITDA: 2019-2024

Historic EBITDA for Mainz Biomed N.V (MYNZ) over the last 6 years, with Dec 2024 value amounting to $21.8 million.

  • Mainz Biomed N.V's EBITDA rose 171.75% to $6.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $26.8 million, marking a year-over-year increase of 177.35%. This contributed to the annual value of $21.8 million for FY2024, which is 18.82% down from last year.
  • Per Mainz Biomed N.V's latest filing, its EBITDA stood at $21.8 million for FY2024, which was down 18.82% from $26.8 million recorded in FY2023.
  • In the past 5 years, Mainz Biomed N.V's EBITDA registered a high of $26.8 million during FY2023, and its lowest value of -$26.4 million during FY2022.
  • Over the past 3 years, Mainz Biomed N.V's median EBITDA value was $21.8 million (recorded in 2024), while the average stood at $7.4 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 1,343.43% in 2021, then spiked by 201.35% in 2023.
  • Mainz Biomed N.V's EBITDA (Yearly) stood at -$673,715 in 2020, then slumped by 1,343.43% to -$9.7 million in 2021, then plummeted by 171.93% to -$26.4 million in 2022, then skyrocketed by 201.35% to $26.8 million in 2023, then declined by 18.82% to $21.8 million in 2024.